Press Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 1, 2015-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced Henri Termeer, industry leader and former CEO of Genzyme, will be a key advisor to the Company.

“I am honored to have Henri Termeer, a pioneer of rare disease companies, serve as an advisor as we seek FDA approval for our lead product candidate and build a rare disease organization,” said Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer. "Henri not only built the first world-leading biotech focused on rare disease, but more importantly created a patient-centric organization, a core value which we will remain deeply committed to at Sarepta.”

“I look forward to working closely with Edward Kaye and the entire Sarepta team during this important time in the Company’s development,” said Henri Termeer. “This is an opportunity for me to continue the work of advancing promising treatments to patients who suffer from rare and life threatening diseases, with eteplirsen, as well as with Sarepta’s pipeline of follow on exons to treat patients with DMD and other rare neuromuscular diseases.”

Henri Termeer is the former chairman, president and chief executive officer of Genzyme Corporation, where he served for nearly three decades until retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20 billion. Mr. Termeer continues to be very active in the areas of humanitarian assistance, policy issues, and innovation in providing access to healthcare. Henri and his wife, Belinda, founded the Termeer Center for Targeted Therapies at Massachusetts General Hospital in 2012. He serves on the boards of numerous scientific and healthcare institutions. He is a Fellow of the American Academy of Arts and Sciences.

About Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other life threatening diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. For more information, please visit us at www.sarepta.com.

Forward-Looking Statements

This press release contains statements that are forward looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “may,” “intends,” “prepares,” “looks,” “potential,” “possible” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to Mr. Termeer’s role as a key advisor to Sarepta; Sarepta’s plan to seek regulatory approval for its lead product candidate and build a rare disease organization; Sarepta’s commitment to the core value of building a patient-centric organization; Mr. Termeer’s plans to continue the work of advancing promising treatments to patients who suffer from rare and life threatening diseases, with eteplirsen, as well as with Sarepta’s pipeline of follow on exons, to treat patients with DMD and other rare neuromuscular diseases.

These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta’s control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: we may not be able to capitalize on Mr. Termeer’s expertise in his role as a key advisor to the Company as we seek to develop and obtain regulatory approval for eteplirsen and our pipeline of product candidates; the FDA may determine that our NDA submission for eteplirsen, even if complete, does not qualify for filing or approval; the additional information and data we collect or have collected for the eteplirsen NDA submission may not be consistent with prior data or results; we may not be able to comply with all FDA requests in a timely manner or at all; and there may be delays in our projected timelines and our expectations may not be accurate with respect to a potential commercialization of eteplirsen for various reasons, including possible limitations of Company resources and regulatory or agency decisions, scale-up of manufacturing may not be successful, we may lack the funding necessary to commercialize eteplirsen or any of our product candidates, the results of the additional eteplirsen trials the Company conducts may not support an NDA filing or approval for eteplirsen and those risks identified under the heading “Risk Factors” in Sarepta’s most recent Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by Sarepta, which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect the Company’s business, results of operations and the trading price of Sarepta’s common stock. You should not place undue reliance on forward-looking statements. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by applicable law or SEC rules.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150701005478/en/

Source: Sarepta Therapeutics, Inc.

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
iestepan@sarepta.com
or
W2O Group
Ryan Flinn, 415-946-1059
Mobile: 510-207-7616
rflinn@w2ogroup.com